IF 3.6 3区 医学 Q2 HEMATOLOGY
Rhea Hans, Charlotte Schwalbach, Roberta H Adams, Holly Miller, Dana Salzberg, Mohamad Sinno, Kristen Beebe, Daniela Giralt, Jennifer Stahlecker, Jeff Crosby, Jefferson Lin, Lucia Mirea, Kevin Land, Alexander Ngwube
{"title":"A Retrospective Analysis of Fresh versus Cryopreserved Allogenic Bone Marrow Transplant within a Pediatric Population: A Change in Practice Due to the COVID-19 Pandemic.","authors":"Rhea Hans, Charlotte Schwalbach, Roberta H Adams, Holly Miller, Dana Salzberg, Mohamad Sinno, Kristen Beebe, Daniela Giralt, Jennifer Stahlecker, Jeff Crosby, Jefferson Lin, Lucia Mirea, Kevin Land, Alexander Ngwube","doi":"10.1016/j.jtct.2024.12.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Several adult studies show mixed reports in clinical outcomes between cryopreserved and fresh stem cell products, with majority reporting no significant differences and others report that there are differences in outcomes. There is limited literature reporting its impact on outcomes in pediatric hematopoietic cell transplantation (HSCT).</p><p><strong>Objective: </strong>To compare clinical outcomes between fresh vs cryopreserved stem cell treatment in pediatric HSCT.</p><p><strong>Study design: </strong>A retrospective chart review was conducted on allogenic HSCT at Phoenix Children's Hospital between January 1, 2016, and March 31, 2023. The study included 181 patients, with 105 receiving fresh stem cell products and 76 receiving cryopreserved products. Clinical outcomes including, neutrophil and platelet recovery, graft versus host disease, immune reconstitution and survival outcome were compared.</p><p><strong>Results: </strong>Study subjects had median follow-up of 997 (range 12-2642) days. 92 patients were treated for a malignant disease (leukemia/lymphoma) and 89 were treated for a non-malignant disease (hemoglobinopathies, immunodeficiency/immune dysregulation, and bone marrow failure). 124 stem cell products were from bone marrow and 57 were from peripheral blood. Comparisons between fresh vs cryopreserved treatments found no significant difference in days to neutrophil engraftment (p=0.47) or platelet engraftment (p=0.94). No difference in the incidence of acute graft versus host disease or chronic graft versus host disease (p = 0.70) between both groups. Immune reconstitution at 365 days post-transplant did not vary significantly between treatment groups for CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD56/16+ NK cells. Overall survival at 2 years was similar in the fresh vs cryopreserved (86.7% vs 84.2%; p = 0.64).</p><p><strong>Conclusion: </strong>These observations suggest that cryopreserved stem cell product is a reasonable alternative with comparable efficacy and potentially offering logistical advantages. Further research with larger pediatric cohorts is recommended to confirm non-inferiority of cryopreserved treatments in pediatric HSCT.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2024.12.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:几项成人研究显示,冷冻保存干细胞产品与新鲜干细胞产品的临床结果报告不一,大多数报告称两者无明显差异,其他报告称两者的结果存在差异。有关其对小儿造血细胞移植(HSCT)结果影响的文献报道有限:比较新鲜干细胞与低温保存干细胞治疗在小儿造血干细胞移植中的临床效果:研究设计:凤凰城儿童医院对2016年1月1日至2023年3月31日期间的异基因造血干细胞移植进行了回顾性病历审查。研究包括181名患者,其中105人接受新鲜干细胞产品,76人接受低温保存产品。临床结果包括中性粒细胞和血小板恢复、移植物抗宿主疾病、免疫重建和存活结果:研究对象的中位随访时间为 997 天(12-2642 天)。92名患者接受了恶性疾病(白血病/淋巴瘤)治疗,89名患者接受了非恶性疾病(血红蛋白病、免疫缺陷/免疫失调和骨髓衰竭)治疗。124个干细胞产品来自骨髓,57个来自外周血。新鲜与低温保存的比较发现,中性粒细胞移植天数(P=0.47)和血小板移植天数(P=0.94)无显著差异。两组急性移植物抗宿主疾病或慢性移植物抗宿主疾病的发生率无差异(p=0.70)。移植后365天的免疫重建在CD4+ T细胞、CD8+ T细胞、CD19+ B细胞和CD56/16+ NK细胞方面,治疗组之间没有显著差异。新鲜组与低温保存组的2年总存活率相似(86.7% vs 84.2%; p = 0.64):这些观察结果表明,低温保存的干细胞产品是一种合理的替代品,疗效相当,并可能提供后勤优势。建议对更大规模的儿科群组进行进一步研究,以确认冷冻保存疗法在儿科造血干细胞移植中的非劣效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Retrospective Analysis of Fresh versus Cryopreserved Allogenic Bone Marrow Transplant within a Pediatric Population: A Change in Practice Due to the COVID-19 Pandemic.

Background: Several adult studies show mixed reports in clinical outcomes between cryopreserved and fresh stem cell products, with majority reporting no significant differences and others report that there are differences in outcomes. There is limited literature reporting its impact on outcomes in pediatric hematopoietic cell transplantation (HSCT).

Objective: To compare clinical outcomes between fresh vs cryopreserved stem cell treatment in pediatric HSCT.

Study design: A retrospective chart review was conducted on allogenic HSCT at Phoenix Children's Hospital between January 1, 2016, and March 31, 2023. The study included 181 patients, with 105 receiving fresh stem cell products and 76 receiving cryopreserved products. Clinical outcomes including, neutrophil and platelet recovery, graft versus host disease, immune reconstitution and survival outcome were compared.

Results: Study subjects had median follow-up of 997 (range 12-2642) days. 92 patients were treated for a malignant disease (leukemia/lymphoma) and 89 were treated for a non-malignant disease (hemoglobinopathies, immunodeficiency/immune dysregulation, and bone marrow failure). 124 stem cell products were from bone marrow and 57 were from peripheral blood. Comparisons between fresh vs cryopreserved treatments found no significant difference in days to neutrophil engraftment (p=0.47) or platelet engraftment (p=0.94). No difference in the incidence of acute graft versus host disease or chronic graft versus host disease (p = 0.70) between both groups. Immune reconstitution at 365 days post-transplant did not vary significantly between treatment groups for CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD56/16+ NK cells. Overall survival at 2 years was similar in the fresh vs cryopreserved (86.7% vs 84.2%; p = 0.64).

Conclusion: These observations suggest that cryopreserved stem cell product is a reasonable alternative with comparable efficacy and potentially offering logistical advantages. Further research with larger pediatric cohorts is recommended to confirm non-inferiority of cryopreserved treatments in pediatric HSCT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信